Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXOPHYLLIN vs ELIXICON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4.
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Approximately 40-60% bound to plasma proteins, primarily albumin. Binding is saturable and may decrease in uremia or with elevated bilirubin. In neonates, protein binding is lower (about 20-30%) due to decreased albumin concentrations.
Approximately 40% bound, primarily to albumin.
Volume of distribution: approximately 0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Theophylline distributes into total body water, with some accumulation in tissues. Vd is increased in neonates (0.6-0.9 L/kg) and decreased in obesity (0.3-0.4 L/kg adjusted for ideal body weight).
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
Oral immediate-release: 90-100% (well absorbed). Oral extended-release: 80-100% (inter- and intra-subject variability exists). Rectal solution: 80-90%. Rectal suppository: 60-70% (erratic absorption). Intravenous: 100%.
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
Theophylline pharmacokinetics are not significantly altered in renal impairment. No dose adjustment recommended for GFR >15 m L/min. For end-stage renal disease (GFR <15 m L/min), monitor serum theophylline concentrations closely as clearance may be reduced; consider 25% dose reduction and follow levels.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
Child-Pugh Class A: Reduce dose by 50% of usual. Child-Pugh Class B: Reduce dose by 50-75% of usual. Child-Pugh Class C: Contraindicated or reduce dose by 80% with close monitoring. Serum theophylline concentration monitoring is mandatory.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Immediate-release: Initial dose 16 mg/kg/day or 400 mg/day (whichever is less) PO divided every 6-8 hours; titrate based on serum theophylline concentration. Typical maintenance: <1 year: 0.2 x age in weeks + 5 mg/kg/day; 1-9 years: 24 mg/kg/day; >9 years: 16 mg/kg/day. Maximum dose 800 mg/day.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Elderly patients (>60 years) have reduced theophylline clearance. Initial dose 300 mg/day PO divided every 8-12 hours; maximum recommended dose 400 mg/day. Monitor serum theophylline concentrations closely and adjust to avoid levels >15 mcg/m L due to increased risk of toxicity.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
No FDA black box warning.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with levels >20 mcg/m L. Use caution in patients with cardiac disorders, hepatic impairment, elderly, and those on medications that alter theophylline metabolism.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Hypersensitivity to theophylline or any component of the formulation; peptic ulcer disease; seizure disorder (unless adequately controlled).
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
Avoid high-caffeine foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. Dietary protein and charcoal-broiled meats may increase clearance, potentially reducing efficacy. Consistency in diet is recommended.
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limited; may be associated with intrauterine growth restriction and neonatal withdrawal if used near term. Second trimester: Risk of tachyarrhythmias and fetal hypoxia due to maternal toxicity. Third trimester: Increased risk of neonatal apnea, jitteriness, and irritability due to transplacental passage. Avoid use unless clearly needed.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Peak milk levels occur 2-4 hours after dose. Infant serum levels are typically low (10-30% of maternal levels). Risk of irritability and jitteriness in infants. Use with caution; monitor infant for adverse effects.
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Due to increased clearance of theophylline in pregnancy (by up to 30-50%), dose adjustments are often required. The half-life may decrease significantly, especially in the second and third trimesters. Consider starting with higher doses or more frequent intervals (e.g., every 6-8 hours). Monitor serum concentrations every 2-4 weeks and adjust to maintain therapeutic levels. Postpartum, clearance may decrease, requiring dose reduction.
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
ELIXOPHYLLIN is a brand name for theophylline elixir. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or COPD. Adjust dose based on smoking status (smokers require higher doses). Drug interactions: cimetidine, ciprofloxacin, fluvoxamine increase levels; phenytoin, carbamazepine, rifampin decrease levels.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, diarrhea, headache, insomnia, irritability, rapid heartbeat, or seizures.,Do not crush or chew extended-release tablets; take elixir with a measuring device for accurate dose.,Notify your doctor if you start or stop smoking, as tobacco use affects how this drug works.,Store at room temperature away from moisture and heat.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXOPHYLLIN vs ELIXICON, answered by our medical review team.
ELIXOPHYLLIN is a Xanthine Bronchodilator that works by Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.. ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXOPHYLLIN and ELIXICON depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXOPHYLLIN is: Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.. The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXOPHYLLIN and ELIXICON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXOPHYLLIN is classified as Category C. Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limite. ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.